Evaluation of a New Closed-System Automated RT-qPCR Assay for the Rapid Detection and Monitoring of Common Nucleophosmin Mutations in Patients with Acute Myeloid Leukemia
Details
Publication Year 2024-07-19,Volume 25,Issue #14,Page 7912
Journal Title
International Journal of Molecular Sciences
Publication Type
Research article
Abstract
Quantitative assessment of nucleophosmin 1 (NPM1) mutation status is integral to evaluating measurable residual disease (MRD) in NPM1-mutated acute myeloid leukemia (AML) patients. In a retrospective study, leftover peripheral blood (PB) specimens (n = 40) which were collected for routine clinical diagnostic evaluations of AML disease burden were tested by both a novel automated RT-qPCR quantitative NPM1 assay (Xpert NPM1 mutation assay) and the NPM1 mutA, mutB&D MutaQuant kit. Based on a Deming regression analysis, there was a high correlation (slope = 0.92; intercept = 0.12; Pearson's r = 0.982) between the quantitative results of the Xpert NPM1 mutation assay and the NPM1 mutA, mutB&D MutaQuant kit. The Xpert test quantitative results are thus highly correlated with the comparator method and the former has potential as a useful alternative for the monitoring of AML patients with a known NPM1 mutation.
Publisher
MDPI
Keywords
*Nucleophosmin; Humans; *Leukemia, Myeloid, Acute/genetics/diagnosis; *Nuclear Proteins/genetics; *Mutation; *Real-Time Polymerase Chain Reaction/methods; Retrospective Studies; Neoplasm, Residual/genetics/diagnosis; Male; Female; Middle Aged; acute myeloid leukemia; minimal residual disease (MRD); monitoring; nucleophosmin (NPM1) mutation; polymerase chain reaction
Department(s)
Pathology
Open Access at Publisher's Site
https://doi.org/10.3390/ijms25147912
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-09-03 05:21:06
Last Modified: 2024-09-03 05:25:14
An error has occurred. This application may no longer respond until reloaded. Reload 🗙